Citations 86
B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL
Arnulf, Bertrand , Patel, Krina K. , Manier, Salomon , Vij, Ravi , Solomon, Scott R. , Delforge, Michel, Truppel-Hartmann, Anna, Yang, Zhihong, Favre-Kontula, Linda, Wu, Frank Shao-Ying , Piasecki, Julia , Rodríguez‐Otero, Paula , Ailawadhi, Sikander , Cavo, Michèle , Nooka, Ajay K. , Callander, Natalie S. , Costa, Luciano J. , Bahlis, Nizar Jacques , Moreau, Philippe , Berdeja, Jesús G. , Cook, Mark , Giralt, Sergio
HemaSphere | May 10, 2023 | Volume: 7 | Issue: S2 | Pages: 7-8
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Rodríguez‐Otero, Paula , Arnulf, Bertrand , Patel, Krina K. , Cavo, Michèle , Manier, Salomon , Vij, Ravi , Solomon, Scott R. , Delforge, Michel , Truppel-Hartmann, Anna, Yang, Zhihong, Favre‐Kontula, Linda, Piasecki, Julia , Cook, Mark , Callander, Natalie, Costa, Luciano J , Bahlis, Nizar J. , Solomon, Scott R , Berdeja, Jesús, Favre-Kontula, Linda, Wu, Fan, Giralt, Sergio , Rodriguez-Otero, Paula , Ailawadhi, Sikander , Nooka, Ajay K. , Callander, Natalie S. , Costa, Luciano J. , Bahlis, Nizar Jacques , Moreau, Philippe , Berdeja, Jesús G. , Wu, Fan
New England Journal of Medicine | February 10, 2023 | Volume: 388 | Issue: 11 | Pages: 1002-1014
Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study
Trudel, Suzanne , Spencer, Andrew , Forsberg, Peter A. , Laubach, Jacob P. , Mateos, María‐Victoria , Kaedbey, Rayan , Krishnan, Amrita , Choeurng, Voleak, Cooper, James Fenimore, Sumiyoshi, Teiko, Wong, Chihunt, Lesokhin, Alexander M. , Richter, Joshua , Cohen, Adam D. , Thomas, Sheeba K. , Bahlis, Nizar Jacques , Costa, Luciano J. , Rodríguez‐Otero, Paula , Berdeja, Jesús G. , Fonseca, Rafaël , Harrison, Simon J
Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4415-4417
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study
Usmani, Saad Z. , Plesner, Torben , Hulin, Cyrille , Goldschmidt, Hartmut , Venner, Christopher P. , Tiab, Mourad, Macro, Margaret , Leleu, Xavier , Pei, Huiling , Krevvata, Maria, Carson, Robin, Borgsten, Fredrik, Kumar, Shaji , Usmani, Saad , Moreau, Philippe , Facon, Thierry T.F. , Bahlis, Nizar Jacques , Raje, Noopur , Orlowski, Robert Z. , Basu, Supratik , Nahi, Hareth , Quach, Hang , O’Dwyer, Michael , Perrot, Aurore , Weisel, Katja C , Frenzel, Laurent
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7297-7300
Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
Kumar, Shaji , Plesner, Torben , Hulin, Cyrille , Venner, Christopher P. , Tiab, Mourad, Macro, Margaret , Leleu, Xavier , Pei, Huiling , Carson, Robin, Borgsten, Fredrik, Goldschmidt, Hartmut , Facon, Thierry T.F. , Weisel, Katja C , Usmani, Saad Z. , Moreau, Philippe , Orlowski, Robert Z. , Bahlis, Nizar Jacques , Basu, Supratik , Nahi, Hareth , Quach, Hang , O’Dwyer, Michael , Perrot, Aurore , Raje, Noopur , Frenzel, Laurent
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10133-10136
Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial
Plesner, Torben , Usmani, Saad Z. , Kumar, Shaji , Hulin, Cyrille , Roussel, Murielle , Delforge, Michel, Karlin, Lionel , Arnulf, Bertrand , Pei, Huiling , Gupta, Niodita, Kaila, Shuchita, Matt, Kathryn, Gries, Katharine S. , Carson, Robin, Borgsten, Fredrik, Usmani, Saad , Roussel, Murielle , Perrot, Aurore , Facon, Thierry T.F. , Bahlis, Nizar Jacques , Orlowski, Robert Z. , Nahi, Hareth , Mollee, Peter , Ramasamy, Karthik , Jaccard, Arnaud , Chari, Ajai , Weisel, Katja C
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1142-1145
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
Kumar, Shaji , Plesner, Torben , Hulin, Cyrille , Goldschmidt, Hartmut , Venner, Christopher P. , Tiab, Mourad, Macro, Margaret , Leleu, Xavier , Pei, Huiling , Krevvata, Maria, Carson, Robin, Borgsten, Fredrik, Moreau, Philippe , Bahlis, Nizar Jacques , Facon, Thierry T.F. , Orlowski, Robert Z. , Basu, Supratik , Nahi, Hareth , Quach, Hang , O’Dwyer, Michael , Perrot, Aurore , Weisel, Katja C , Raje, Noopur , Frenzel, Laurent , Usmani, Saad Z.
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10150-10153
IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma
Welsh, Seth J. , Zhu, Yuan Xiao , Du, Megan T. , Garbitt, Victoria M. , Meurice, Nathalie , Todd, Kennedi T. , Brown, Sochilt , Alvarado, Yuliza Tafoya , Hammond, Zachary J., Cuc, Nicklus H. , Wittenberg, Courtney , Herzog, Camille , Kuehl, W. Michael, Chesi, Marta, Barwick, Benjamin G. , Meermeier, Erin W. , Riggs, Daniel L. , Shi, Chang-Xin , Sharik, Meaghen E. , Stein, Caleb K. , Petit, Joachim L. , Fonseca, Rodrigo , Boise, Lawrence , Bahlis, Nizar Jacques , Neri, Paola , Chesi, Marta , Bergsagel, P. Leif
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12997-12997
Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax
Dunbar, Fengjiao, Wang, Xifeng , Li, Xiaotong , Mantis, Christine, Bueno, Orlando F. , Kumar, Shaji , Epling-Burnette, PK, Sharon, David M. , Jung, Paul , Touzeau, Cyrille , Moreau, Philippe , Harrison, Simon J , Costa, Luciano J. , Kaufman, Jonathan L. , Bahlis, Nizar Jacques , Ross, Jeremy A.
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4242-4244
P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY
Facon, T., Kumar, Seema, Plesner, Torben , Goldschmidt, H., Perrot, A., Venner, Chris , Mace, Joseph R., Tiab, Mourad, Macro, M. , Frenzel, L., Leleu, Xavier , Pei, H., Borgsten, F., Usmani, S. Z., Moreau, Philippe , Bahlis, Nizar Jacques , O’Dwyer, Michael , Weisel, Katja C , Raje, Noopur
HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 826-827